<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04129775</url>
  </required_header>
  <id_info>
    <org_study_id>413-201901</org_study_id>
    <nct_id>NCT04129775</nct_id>
  </id_info>
  <brief_title>OTO-413 in Subjects With Speech-in-Noise Hearing Impairment</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase 1/2 Study of OTO-413 Given as a Single Intratympanic Injection in Subjects With Speech-in-noise Hearing Impairment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otonomy, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Otonomy, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and exploratory efficacy&#xD;
      of OTO-413 administered as an intratympanic injection for the treatment of speech-in-noise&#xD;
      hearing impairment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Treatment Emergent Adverse Events (Safety)</measure>
    <time_frame>Reported or observed during or after dosing (Day 1) up to the end of study (Day 85 - 12 weeks after dosing)</time_frame>
    <description>An adverse event (AE) is any unfavorable and unintended diagnosis, symptom, sign, syndrome or disease which occurs during the study, having been absent at baseline, or if present at baseline, appears to worsen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Otoscopic Examinations (Safety)</measure>
    <time_frame>After dosing (Day 1) up to end of study (Day 85 - 12 weeks after dosing)</time_frame>
    <description>Clinically significant change form Baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Audiometry (Safety)</measure>
    <time_frame>After dosing (Day 1) up to end of study (Day 85 - 12 weeks after dosing)</time_frame>
    <description>Clinically significant change from Baseline</description>
  </primary_outcome>
  <other_outcome>
    <measure>Speech-in-noise Hearing Tests</measure>
    <time_frame>Screening, Baseline, 2 weeks (dependent on dose group), 4 weeks, 8 weeks and 12 weeks after dosing</time_frame>
    <description>Ability to hear over noise</description>
  </other_outcome>
  <other_outcome>
    <measure>Electrophysiological Endpoint (dependent on dose group)</measure>
    <time_frame>At Screening, 4 weeks, 8 weeks and 12 weeks after dosing</time_frame>
    <description>Electrophysiological test of auditory brainstem response to auditory stimuli</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Global Impression of Change</measure>
    <time_frame>At 2 weeks (dependent on dose group), 4 weeks, 8 weeks and 12 weeks after dosing</time_frame>
    <description>Change in overall hearing status, ranging from very much worse (-3) to very much improved (+3)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Sensorineural Hearing Loss</condition>
  <arm_group>
    <arm_group_label>OTO-413</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTO-413</intervention_name>
    <description>Single intratympanic injection of Brain-Derived Neurotrophic Factor (BDNF)</description>
    <arm_group_label>OTO-413</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single intratympanic injection of placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has audiometrically-defined normal hearing or up to moderately severe hearing&#xD;
             impairment.&#xD;
&#xD;
          -  Subject has self-reported difficulty hearing in noisy environments for at least 6&#xD;
             months prior to Screening.&#xD;
&#xD;
          -  Subject exhibited a speech-in-noise hearing deficit in at least one ear.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject is pregnant or lactating.&#xD;
&#xD;
          -  Subject has the following hearing disorders or any other hearing disorders that may&#xD;
             impact the efficacy assessments or safety of the subject in the opinion of the&#xD;
             Investigator: Meniere's disease, congenital hearing loss, or genetic sensorineural&#xD;
             hearing loss.&#xD;
&#xD;
          -  Subject has a cochlear implant or consistently uses a hearing aid.&#xD;
&#xD;
          -  Subject has worked at least 5 years as a professional musician or has had at least 15&#xD;
             years of formal musical training.&#xD;
&#xD;
          -  Subject self-reports bothersome, subjective tinnitus and is consistently aware of&#xD;
             their tinnitus throughout much of the waking day.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Study Manager</last_name>
    <email>otonomyclinicaltrials@otonomy.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Colorado Otolaryngology Associates LLC dba Colorado ENT &amp; Allergy</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80923</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Davis</last_name>
      <phone>719-867-7804</phone>
      <email>Mdavis@coloradoent.com</email>
    </contact>
    <investigator>
      <last_name>Bryan Davis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>South Florida ENT Associates or Research Centers of America</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33156</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of South Florida</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victoria Sanchez</last_name>
      <phone>813-974-1262</phone>
      <email>arctlab@usf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Advanced ENT and Allergy, PLLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhonda Dase</last_name>
      <phone>502-893-0159</phone>
      <phone_ext>1184</phone_ext>
      <email>rdase@advancedentandallergy.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Piedmont Ear, Nose &amp; Throat Associates</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jessica Mack-Gill</last_name>
      <phone>336-768-3361</phone>
      <phone_ext>222</phone_ext>
      <email>jmack@piedmontent.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>JBR Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Bertoch, MD</last_name>
      <phone>801-261-2000</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eastern Virginia Medical School, Department of Otolaryngology</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Addy Tham</last_name>
      <phone>757-388-6264</phone>
      <email>ThamA@evms.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 14, 2019</study_first_submitted>
  <study_first_submitted_qc>October 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 17, 2019</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hearing loss</keyword>
  <keyword>speech-in-noise</keyword>
  <keyword>synaptopathy</keyword>
  <keyword>hearing impairment</keyword>
  <keyword>hidden hearing loss</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hearing Loss</mesh_term>
    <mesh_term>Deafness</mesh_term>
    <mesh_term>Hearing Loss, Sensorineural</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

